All In Biotech

Drug Trial Radar · NCT06034977

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Genotype Selected, Randomized, Open Label, Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

Dec 1, 2023

Primary completion

Jul 23, 2026

Study completion Jul 23, 2026

Sponsor

Lead sponsor
Chang Gung Memorial HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the clinical outcomes of Lenvatinib treatment alone or Lenvatinib + ADI-PEG20 combination treatment in advanced HCC patients with BCLC stage C.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • ADI-PEG20Drug

    Lenvatinib + ADI-PEG20 combination treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: 2 years after the last enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chang Gung Memorial Hospital, Linkou branch

    Taoyuan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.